Skip to main content
Erschienen in:

01.05.2015 | Leitthema

Therapiemonitoring mit Perfusionsbildgebung in der Computertomographie

verfasst von: Dr. M.C. Spoerl, J.P. Kühn, S. Fischer, A.H. Mahnken

Erschienen in: Die Onkologie | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die kontrastmittelgestützte Computertomographie (CT) besitzt in der Onkologie aufgrund ihrer Geschwindigkeit und exzellenten Bildqualität einen festen Stellenwert. Die morphologische Darstellung von Tumoren und auch die Beurteilung eines Therapieansprechens im zeitlichen Intervall sind bevorzugte Einsatzgebiete.

Ziel der Arbeit

Mittels der dynamischen CT-Perfusionsbildgebung können Tumore nichtinvasiv unabhängig ihrer Größe funktionell charakterisiert werden. Diese Arbeit gibt einen Überblick über die Funktionsweise und die klinischen Einsatzgebiete der CT-Perfusion vor dem Hintergrund der onkologischen Bildgebung.

Material und Methoden

Es wurde eine selektive Literaturrecherche zum Thema CT-Perfusionsbildgebung und Therapiemonitoring durchgeführt.

Ergebnisse

CT-Perfusion kann unter Nutzung der Vorteile der CT-Bildgebung frühzeitig den Therapieerfolg erfassen und zeitgleich Rezidive ausschließen.
Literatur
2.
Zurück zum Zitat Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefPubMed Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefPubMed
3.
Zurück zum Zitat Gomes FG et al (2013) Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci 92(2):101–107CrossRefPubMedCentralPubMed Gomes FG et al (2013) Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci 92(2):101–107CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat Cuenod CA et al (2006) Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging 31(2):188–193CrossRefPubMed Cuenod CA et al (2006) Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging 31(2):188–193CrossRefPubMed
5.
Zurück zum Zitat Fox SB, Harris AL (2004) Histological quantitation of tumour angiogenesis. APMIS 112(7–8):413–430 (Munksgaard International Publishers) Fox SB, Harris AL (2004) Histological quantitation of tumour angiogenesis. APMIS 112(7–8):413–430 (Munksgaard International Publishers)
6.
Zurück zum Zitat Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 94(12):883–893CrossRefPubMed Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 94(12):883–893CrossRefPubMed
7.
Zurück zum Zitat Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216CrossRefPubMed Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216CrossRefPubMed
8.
Zurück zum Zitat Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed
9.
Zurück zum Zitat Jiang T et al (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 47(1):11–17CrossRefPubMed Jiang T et al (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 47(1):11–17CrossRefPubMed
10.
Zurück zum Zitat Lencioni R, Llovet J (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60CrossRefPubMed Lencioni R, Llovet J (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60CrossRefPubMed
11.
Zurück zum Zitat Choi H et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759CrossRefPubMed Choi H et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759CrossRefPubMed
12.
Zurück zum Zitat Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23(14):3243–3256CrossRefPubMed Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23(14):3243–3256CrossRefPubMed
14.
Zurück zum Zitat Axel L (1980) Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology 137(3):679–686CrossRefPubMed Axel L (1980) Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology 137(3):679–686CrossRefPubMed
15.
Zurück zum Zitat Axel L (1983) Tissue mean transit time from dynamic computed tomography by a simple deconvolution technique. Invest Radiol 18(1):94–99CrossRefPubMed Axel L (1983) Tissue mean transit time from dynamic computed tomography by a simple deconvolution technique. Invest Radiol 18(1):94–99CrossRefPubMed
16.
Zurück zum Zitat Miles KA, Hayball MP, Dixon AK (1993) Functional images of hepatic perfusion obtained with dynamic CT. Radiology 188(2):405–411CrossRefPubMed Miles KA, Hayball MP, Dixon AK (1993) Functional images of hepatic perfusion obtained with dynamic CT. Radiology 188(2):405–411CrossRefPubMed
18.
Zurück zum Zitat Sahani DV, Perfusion CT (2010) An overview of technique and clinical applications in proc. Intl Soc Mag Reson Med 18:1–12 Sahani DV, Perfusion CT (2010) An overview of technique and clinical applications in proc. Intl Soc Mag Reson Med 18:1–12
19.
Zurück zum Zitat Ng Q-S et al (2006) Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology 239(2):547–553CrossRefPubMed Ng Q-S et al (2006) Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology 239(2):547–553CrossRefPubMed
20.
Zurück zum Zitat Goh V et al (2008) Effect of temporal interval between scan acquisitions on quantitative vascular parameters in colorectal cancer: implications for helical volumetric perfusion CT techniques. Am J Roentgenol 191(6):W288–W292CrossRef Goh V et al (2008) Effect of temporal interval between scan acquisitions on quantitative vascular parameters in colorectal cancer: implications for helical volumetric perfusion CT techniques. Am J Roentgenol 191(6):W288–W292CrossRef
21.
Zurück zum Zitat Hansen M et al (2013) Computed tomography (CT) perfusion in abdominal cancer: technical aspects. Diagnostics 3(2):261–270CrossRef Hansen M et al (2013) Computed tomography (CT) perfusion in abdominal cancer: technical aspects. Diagnostics 3(2):261–270CrossRef
22.
Zurück zum Zitat Kambadakone AR, Sahani DV (2009) Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 47(1):161–178CrossRefPubMed Kambadakone AR, Sahani DV (2009) Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 47(1):161–178CrossRefPubMed
24.
Zurück zum Zitat Wintermark M et al (2002) Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke 33(8):2025–2031CrossRefPubMed Wintermark M et al (2002) Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke 33(8):2025–2031CrossRefPubMed
25.
Zurück zum Zitat Lee R et al (2004) Use of CT perfusion to differentiate between brain tumour and cerebral infarction. Cerebrovasc Dis 18(1):77–83CrossRefPubMed Lee R et al (2004) Use of CT perfusion to differentiate between brain tumour and cerebral infarction. Cerebrovasc Dis 18(1):77–83CrossRefPubMed
26.
Zurück zum Zitat Jain R (2011) Perfusion CT imaging of brain tumors: an overview. AJNR Am J Neuroradiol 32(9):1570–1577CrossRefPubMed Jain R (2011) Perfusion CT imaging of brain tumors: an overview. AJNR Am J Neuroradiol 32(9):1570–1577CrossRefPubMed
28.
Zurück zum Zitat Jain R et al (2007) First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 61(4):778–786 (discussion 786–787)CrossRefPubMed Jain R et al (2007) First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 61(4):778–786 (discussion 786–787)CrossRefPubMed
29.
Zurück zum Zitat Jain R et al (2011) Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol 32(4):658–663CrossRefPubMed Jain R et al (2011) Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol 32(4):658–663CrossRefPubMed
30.
Zurück zum Zitat Ryken TC et al (2014) The role of imaging in the management of progressive glioblastoma. J Neurooncol 118(3):435–460CrossRefPubMed Ryken TC et al (2014) The role of imaging in the management of progressive glioblastoma. J Neurooncol 118(3):435–460CrossRefPubMed
31.
Zurück zum Zitat Gahramanov S et al (2013) Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with Ferumoxytol versus gadoteridol and correlation with survival. Radiology 266(3):842–852CrossRefPubMedCentralPubMed Gahramanov S et al (2013) Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with Ferumoxytol versus gadoteridol and correlation with survival. Radiology 266(3):842–852CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat Hygino da Cruz LC et al (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978–1985CrossRef Hygino da Cruz LC et al (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978–1985CrossRef
33.
Zurück zum Zitat Kiessling F et al (2004) Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol 14(7):1226–1233PubMed Kiessling F et al (2004) Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol 14(7):1226–1233PubMed
34.
Zurück zum Zitat Lind JSW et al (2010) Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 20(12):2890–2898CrossRefPubMedCentralPubMed Lind JSW et al (2010) Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol 20(12):2890–2898CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat Therasse P (2002) Measuring the clinical response. What does it mean? Eur J Cancer 38(14):1817–1823CrossRefPubMed Therasse P (2002) Measuring the clinical response. What does it mean? Eur J Cancer 38(14):1817–1823CrossRefPubMed
36.
Zurück zum Zitat Wang J et al (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193(4):1090–1096CrossRefPubMed Wang J et al (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193(4):1090–1096CrossRefPubMed
37.
Zurück zum Zitat Garcia-Barros M (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622):1155–1159CrossRefPubMed Garcia-Barros M (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622):1155–1159CrossRefPubMed
38.
Zurück zum Zitat Weigel C et al (2006) Laser ablation of lung metastases: results according to diameter and location. Eur Radiol 16(8):1769–1778CrossRefPubMed Weigel C et al (2006) Laser ablation of lung metastases: results according to diameter and location. Eur Radiol 16(8):1769–1778CrossRefPubMed
39.
Zurück zum Zitat Rosenberg C et al (2009) Laser ablation of metastatic lesions of the lung: long-term outcome. Am J Roentgenol 192(3):785–792CrossRef Rosenberg C et al (2009) Laser ablation of metastatic lesions of the lung: long-term outcome. Am J Roentgenol 192(3):785–792CrossRef
40.
Zurück zum Zitat Hegenscheid K et al (2010) Assessing early vascular changes and treatment response after laser-induced thermotherapy of pulmonary metastases with perfusion CT: initial experience. Am J Roentgenol 194(4):1116–1123CrossRef Hegenscheid K et al (2010) Assessing early vascular changes and treatment response after laser-induced thermotherapy of pulmonary metastases with perfusion CT: initial experience. Am J Roentgenol 194(4):1116–1123CrossRef
41.
Zurück zum Zitat Mahnken AH, Pereira PL, Baère T de (2013) Interventional oncologic approaches to liver metastases. Radiology 266(2):407–430CrossRefPubMed Mahnken AH, Pereira PL, Baère T de (2013) Interventional oncologic approaches to liver metastases. Radiology 266(2):407–430CrossRefPubMed
42.
Zurück zum Zitat Mahnken AH et al (2011) Volumetric arterial enhancement fraction predicts tumor recurrence after hepatic radiofrequency ablation of liver metastases: initial results. Am J Roentgenol 196(5):W573–W579CrossRef Mahnken AH et al (2011) Volumetric arterial enhancement fraction predicts tumor recurrence after hepatic radiofrequency ablation of liver metastases: initial results. Am J Roentgenol 196(5):W573–W579CrossRef
43.
Zurück zum Zitat Kan Z et al (2005) Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model 1. Radiology 237(1):144–150CrossRefPubMed Kan Z et al (2005) Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model 1. Radiology 237(1):144–150CrossRefPubMed
44.
Zurück zum Zitat Yang L et al (2012) Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma. J Comput Assist Tomogr 36(2):226–230CrossRefPubMed Yang L et al (2012) Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma. J Comput Assist Tomogr 36(2):226–230CrossRefPubMed
45.
Zurück zum Zitat Meijerink MR et al (2009) Early detection of local RFA site recurrence using total liver volume perfusion CT initial experience. Acad Radiol 16(10):1215–1222CrossRefPubMed Meijerink MR et al (2009) Early detection of local RFA site recurrence using total liver volume perfusion CT initial experience. Acad Radiol 16(10):1215–1222CrossRefPubMed
46.
Zurück zum Zitat Ippolito D et al (2012) Viable residual tumor tissue after radiofrequency ablation treatment in hepatocellular carcinoma: evaluation with CT perfusion. Abdom Imaging 38(3):502–510CrossRef Ippolito D et al (2012) Viable residual tumor tissue after radiofrequency ablation treatment in hepatocellular carcinoma: evaluation with CT perfusion. Abdom Imaging 38(3):502–510CrossRef
47.
Zurück zum Zitat Grözinger G, Grözinger A, Horger M (2014) The role of volume perfusion CT in the diagnosis of pathologies of the pancreas. Rofo 186(12):1082–1093CrossRefPubMed Grözinger G, Grözinger A, Horger M (2014) The role of volume perfusion CT in the diagnosis of pathologies of the pancreas. Rofo 186(12):1082–1093CrossRefPubMed
49.
Zurück zum Zitat Sahani DV et al (2005) Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234(3):785–792CrossRefPubMed Sahani DV et al (2005) Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234(3):785–792CrossRefPubMed
50.
Zurück zum Zitat Bellomi M et al (2007) CT Perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience 1. Radiology 244(2):486–493CrossRefPubMed Bellomi M et al (2007) CT Perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience 1. Radiology 244(2):486–493CrossRefPubMed
51.
Zurück zum Zitat Ng CS et al (2011) Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. Am J Roentgenol 196(3):569–576CrossRef Ng CS et al (2011) Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. Am J Roentgenol 196(3):569–576CrossRef
52.
Zurück zum Zitat Sahani DV et al (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue – initial experience 1. Radiology 243(2):736–743CrossRefPubMed Sahani DV et al (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue – initial experience 1. Radiology 243(2):736–743CrossRefPubMed
53.
Zurück zum Zitat Meijerink MR et al (2008) Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases. Eur Radiol 18(10):2345–2354CrossRefPubMed Meijerink MR et al (2008) Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases. Eur Radiol 18(10):2345–2354CrossRefPubMed
54.
Zurück zum Zitat Lee TY et al (1990) Quantitative computed tomography of the brain with xenon enhancement: a phantom study with the GE9800 scanner. Phys Med Biol 35(35):925–935CrossRefPubMed Lee TY et al (1990) Quantitative computed tomography of the brain with xenon enhancement: a phantom study with the GE9800 scanner. Phys Med Biol 35(35):925–935CrossRefPubMed
55.
Zurück zum Zitat Negi N et al (2012) Hepatic CT perfusion measurements: a feasibility study for radiation dose reduction using new image reconstruction method. Eur J Radiol 81(11):3048–3054 (Elsevier Ireland Ltd.)CrossRefPubMed Negi N et al (2012) Hepatic CT perfusion measurements: a feasibility study for radiation dose reduction using new image reconstruction method. Eur J Radiol 81(11):3048–3054 (Elsevier Ireland Ltd.)CrossRefPubMed
56.
Zurück zum Zitat Martirosian P et al (2010) Magnetic resonance perfusion imaging without contrast media. Eur J Nucl Med Mol Imaging 37(Suppl 1):S52–S64CrossRefPubMed Martirosian P et al (2010) Magnetic resonance perfusion imaging without contrast media. Eur J Nucl Med Mol Imaging 37(Suppl 1):S52–S64CrossRefPubMed
Metadaten
Titel
Therapiemonitoring mit Perfusionsbildgebung in der Computertomographie
verfasst von
Dr. M.C. Spoerl
J.P. Kühn
S. Fischer
A.H. Mahnken
Publikationsdatum
01.05.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe 5/2015
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-014-2814-z

Weitere Artikel der Ausgabe 5/2015

Der Onkologe 5/2015 Zur Ausgabe

Algorithmus und Klassifikation

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.